Flow Cytometry (FACS), Immunoprecipitation (IP), Immunocytochemistry (ICC), Cytometry by Time of Flight (CyTOF)
Spezifität
The mouse monoclonal antibody GCP-05 recognizes extracellular domain (preferentially in native form) of glutamate carboxypeptidase II (NAALADase, FOLH1, PSMA), an approximately 95-110 kDa transmembrane glycoprotein expressed mainly in tumour neovasculatures, nervous system and jejunum, which is an important prostate tumour marker.
Phosphate buffered saline (PBS), pH 7.4, 15 mM sodium azide
Konservierungsmittel
Sodium azide
Vorsichtsmaßnahmen
This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Handhabung
Do not freeze.
Lagerung
4 °C
Informationen zur Lagerung
Store at 2-8°C. Do not freeze.
Tykvart, Navrátil, Sedlák, Corey, Colombatti, Fracasso, Koukolík, Ba?inka, Sácha, Konvalinka: "Comparative analysis of monoclonal antibodies against prostate-specific membrane antigen (PSMA)." in: The Prostate, Vol. 74, Issue 16, pp. 1674-90, (2014) (PubMed).
Sácha, Zámecník, Barinka, Hlouchová, Vícha, Mlcochová, Hilgert, Eckschlager, Konvalinka: "Expression of glutamate carboxypeptidase II in human brain." in: Neuroscience, Vol. 144, Issue 4, pp. 1361-72, (2007) (PubMed).
Barinka, Sácha, Sklenár, Man, Bezouska, Slusher, Konvalinka: "Identification of the N-glycosylation sites on glutamate carboxypeptidase II necessary for proteolytic activity." in: Protein science : a publication of the Protein Society, Vol. 13, Issue 6, pp. 1627-35, (2004) (PubMed).
Folate hydrolase 1,Glutamate carboxypeptidase II (GCPII), also known as N-acetyl-alpha-linked acidic dipeptidase I (NAALADase I), folate hydrolase (FOLH1), and prostate-specific membrane antigen (PSMA), is an approximately 95-110 kDa type II transmembrane glycoprotein expressed in various tissues. In nervous system GCPII cleaves abundant N-acetylaspartylglutamate, which is released from neurons in a calcium-dependent manner, to N-acetylaspartate and glutamate. As immoderate glutamate concentration is neurotoxic, GCPII contributes to pathological conditions regarding e.g. Alzheimer´s disease, Huntington´s disease, epilepsy, schizophrenia, stroke or neuropathic pain and appears to be an interesting therapeutic target. In jejunum GCPII hydrolyzes pteroylpoly-gamma-glutamate to folate and glutamate, enabling folate to be absorbed by gastrointestinal tract. GCPII, which is present in a number of tissues at low levels, is overexpressed in neovasculature of most solid tumours and is a target enzyme for diagnosis and treatment of prostate cancer. Normal human prostate express more mRNA coding for a cytosolic GCPII form truncated at the N-terminus (PSM´) than mRNA for membrane-bound GCPII, and this ratio is reversed upon malignant transformation.,GCP2, FOLH1, NAALADase I, PGGCP, FGGCP, FGCP,